Interleukin-34 and Disease Activity in Systemic Lupus Erythematosus Patients

Rizki Luly Ya Fatwa Pulungan, Ratna Akbari Ganie, Zuhrial Zubir


Systemic Lupus Erythematosus (SLE) is characterized by exacerbation and remission, which needs close monitoring of
the disease activity. Systemic lupus erythematosus disease activity can be determined by the SLE Disease Activity Index
(SLEDAI) score. Evaluation of the disease activity is essential to be a guidance for treatment. Interleukin-34 (IL-34) is related
to the pathogenesis of SLE. Serum IL-34 can be a candidate marker to evaluate SLE disease activity, and it is correlated with
the SLEDAI score. This study aimed to determine the correlation between IL-34 level and disease activity in SLE patients
based on the SLEDAI (Mex-SLEDAI) score. An observational analytical study with a cross-sectional design was carried out in
six months (June-November 2019) in 27 SLE patients in the Department of Internal Medicine, Faculty of Medicine, Sumatera
Utara University/Adam Malik General Hospital, Medan. Systemic lupus erythematosus disease activity was measured based
on the Mex-SLEDAI score. Serum and urine were collected to obtain the Mex-SLEDAI score and IL-34 level. IL-34 level was
measured in all subjects by using Enzyme-Linked Immunosorbent Assay (ELISA). Spearman correlation test was used to
determine the correlation between IL-34 level and disease activity in SLE patients based on the SLEDAI (Mex-SLEDAI) score.
There was a significant correlation between IL-34 level and disease activity in SLE patients based on SLEDAI (Mex-SLEDAI)
score (r=0.965, p < 0.001). Further studies were needed with a sample of SLE patients in a balanced proportion based on
their disease activity to obtain representative IL-34 levels in SLE patients based on their disease activity.


Systemic lupus erythematosus, interleukin-34, SLEDAI, Mex-SLEDAI

Full Text:



Xie HH, Shen H, Zhang L, Cui MY, Xia LP, Lu J. Elevated

serum interleukin-34 level in patients with systemic

lupus erythematosus is associated with disease

activity. Sci Rep, 2018; 8(1): 3462.

Baghdadi M, Umeyama Y, Hama N, Kobayashi T, Han

N, Wada H, et al. Interleukin-34, a comprehensive

review. Journal of Leukocyte Biology, 2018; 104:


Guillonneau C, Bézie S, Aegon I. Immunoregulatory

properties of the cytokine IL-34. Cell Mol Life Sci, 2017;

(14): 2569-86.

Kementerian Kesehatan Republik Indonesia. Infodatin

situasi lupus di Indonesia 2017 [Internet]. 2017; 8.



-2017.pdf (accessed 2 February, 2019).

Kasjmir YI, Handono K, Wijaya LK, Hamijoyo L, Albar Z,

Kalim H, et al. Rekomendasi Perhimpunan

Reumatologi Indonesia untuk diagnosis dan

pengelolaan lupus eritematosus sistemik. Jakarta,

Perhimpunan Reumatologi Indonesia, 2011; 1–54.

Y. Santamaria-Alza, JD. Sanchez-Bautiista, J.

Fajardo-Rivero CLF-P. Comparison of disease activity

scores predicting mortality in patients with systemic

lupus erythematosus in Columbia. BMJ, 2019; 1090:


Wang H, Cao J, Lai X. Serum interleukin-34 levels are

elevated in patients with systemic lupus

erythematosus. Molecules, 2017; 22(1): 35.

Wallace DJ, Hahn BH. Dubois'lupus erythematosus

and related syndromes. Ninth Ed., Sydney, Elsevier Inc,

; 772.

Saleh AM, Kurniati N, Syarif BH. Penilaian aktivitas

penyakit lupus eritematosus sistemik dengan skor

SLEDAI di Departemen Ilmu Kesehatan Anak RSCM.

Sari Pediatr, 2016; 16(4): 292.

Atkinson JP, Yu CY. The complement system in

systemic lupus erythematosus. In: Systemic lupus

erythematosus: Basic, applied, and clinical aspects.

USA, Elsevier Inc, 2016; 81–112.

Finzel S, Schaffer S, Rizzi M, Voll RE. Pathogenesis of

systemic lupus erythematosus. Zeitschrift fur

Rheumatologie, 2018; 77: 789–98.

Adamichou C, Bertsias G. Flares in systemic lupus

erythematosus: Diagnosis, risk factors, and preventive

strategies. Mediterranean Journal of Rheumatology,

; 28(1): 4–12.

Baghdadi M, Endo H, Tanaka Y, Wada H, Ichiro SK.

Interleukin 34, from pathogenesis to clinical

applications [Internet]. Cytokine. Elsevier, 2017; 99:

–47. Available from:

j.cyto.2017.08.020 (accessed 2 February, 2019).

Masteller EL, Wong BR. Targeting IL-34 in chronic

inflammation. Drug Discov today [Internet]. 2014;

(8): 1212–6. Available from:

1016/j.drudis.2014.05.016 (accessed 2 February,


Ge Y, Huang M, Yao YM. Immunomodulation of

interleukin-34 and its potential significance as a

disease biomarker and therapeutic target.

International Journal of Biological Sciences, 2019; 15:




  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.